Supriya Announce Agreement To Market Plasma Nutrition’s IoProtein In India

Mumbai : API company Supriya Lifescience has announced a recent collaboration with Plasma Nutrition, a US-based nutrition company located in Delaware.

The strategic partnership involves an exclusive technology licensing agreement, granting Supriya Lifescience the sole rights for manufacturing and marketing Ingredient Optimised Protein (ioProtein) in India.

The primary purpose of this collaboration is to bring the optimised protein into the Indian market. ioProtein is a patented process (patent pending in the US) This revolutionary protein powder is designed for use as protein supplements and boasts a significant advantage, and it is highly bioavailable. This means that higher amounts of proteins are absorbed quickly by the body, providing consumers with a more effective and efficient protein supplement.

During the term of the agreement, Supriya Lifescience will lead the manufacturing and marketing of ioProtein in India. This marks the introduction of a new category of protein powders in the Indian market, and it is relatively healthier compared to other popular protein powders available through various gyms, general stores, and digital marketing channels.

“We are thrilled to be the exclusive partner of Plasma Nutrition, in introducing the innovative ioProtein to the Indian market,” said Dr Saloni Wagh, Executive Director at Supriya Lifescience.

“This strategic partnership represents our commitment to providing high-nutrition solutions to consumers in India. With ioProtein’s high bioavailability and its unmatched advantage, we are confident that the ‘IO’ technology will revolutionise the nutrition industry and become the preferred choice for health-conscious individuals,” Dr Wagh added.

“We are excited to collaborate with Supriya Lifescience and bring our patented ioProtein technology to India,” said Chris Flynn-Rozanski, co-founder & CEO at Plasma Nutrition.

“India’s rapidly growing demand for protein supplements present an excellent opportunity for us to introduce this highly bioavailable protein powder, which has already been well-received in other markets. We believe this partnership will create a new standard for protein supplementation in India,” Flynn-Rozanski said.

Related Posts

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’